Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Adherium Ltd. ( (AU:ADR) ) has issued an update.
Adherium Ltd. announced a change in the director’s interest, with Keven Gessner acquiring 4,000,000 fully paid ordinary shares and 4,000,000 unlisted options. This change, approved at the recent Annual General Meeting, signifies a strategic move to strengthen the company’s leadership stake, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (AU:ADR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Adherium Ltd. stock, see the AU:ADR Stock Forecast page.
More about Adherium Ltd.
Adherium Ltd. operates in the healthcare technology industry, focusing on providing digital health solutions. The company is known for its innovative products that enhance medication adherence and patient outcomes, primarily targeting respiratory conditions.
Technical Sentiment Signal: Sell
Current Market Cap: A$10.05M
See more data about ADR stock on TipRanks’ Stock Analysis page.